The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyae155 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Taku Naiki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objective
The aim of this study was to compare prognostic outcomes of administering first- or second-generation androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer and to find prognostic indicators.
Methods
This retrospective study included 198 patients with non-metastatic castration-resistant prostate cancer from 14 institutions associated with Tokai Urologic Oncology Research Seminar. Forty-two patients were treated with combined androgen blockade using first-generation inhibitors (bicalutamide or flutamide), and 156 were treated with second-generation inhibitors (abiraterone/enzalutamide or apalutamide/darolutamide) after primary androgen deprivation therapy failure. We compared survival outcomes of combined androgen blockade using first-generation inhibitors and second-generation inhibitor treatments, and analyzed clinicopathological or serum parameters and survival outcome.
Results
Combined androgen blockade and second-generation androgen receptor signaling inhibitor groups demonstrated median progression-free survival of 10.2 (95% confidence interval: 5.5–12.3) and 26.0 (95% confidence interval: 21.9–38.4; P < 0.001) months, respectively. Cut-off levels for clinical biomarkers were targeted to <0.2 ng/ml prostate-specific antigen levels 3 months after treatment initiation for non-metastatic castration-resistant prostate cancer; the patient group that achieved this showed better progression-free survival (median 14.7 months, 95% confidence interval: 10.3–23.9 not achieved, median not applicable, 95% confidence interval: 24.6–not applicable achieved; P < 0.00001). Multivariate analysis revealed significant prognostic factors: second-generation androgen receptor signaling inhibitor as first-line treatment (odds ratio: 5.05, 95% confidence interval: 1.54–16.6) and a high hemoglobin level (odds ratio: 2.92, 95% confidence interval: 1.26–6.76).
Conclusions
Our findings suggested prostate-specific antigen < 0.2 ng/ml after 3 months may be a practical prognostic indicator of survival outcomes in non-metastatic castration-resistant prostate cancer. Patients showing a high hemoglobin level should be intensively treated with second-generation androgen receptor signaling inhibitors rather than combined androgen blockade using first-generation inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Urology, Fujita Medical University, Nagoya, Japan.
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Urology, Gifu University, Gifu, Japan.
ORCID-Profile: Taku Naiki, Kiyoshi Takahara
Zitieren
APA
Naiki, T., Takahara, K., Watanabe, H., Nakane, K., Sugiyama, Y., Koie, T., Shiroki, R., Miyake, H., & Yasui, T. (2025). The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae155
Vancouver
Naiki T, Takahara K, Watanabe H, Nakane K, Sugiyama Y, Koie T, et al. The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae155
BibTeX
@article{Naiki2025,
author = {Naiki, Taku and Takahara, Kiyoshi and Watanabe, Hiromitsu and Nakane, Keita and Sugiyama, Yosuke and Koie, Takuya and Shiroki, Ryoichi and Miyake, Hideaki and Yasui, Takahiro},
title = {The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyae155}
}
EUVIMED